Mannkind (MNKD) Cash & Current Investments (2010 - 2026)
Mannkind (MNKD) reported Cash & Current Investments of $134.6 million for Q1 2026, down 26.15% year-over-year from $182.3 million in Q1 2025, and down 21.44% quarter-over-quarter from $171.3 million in Q4 2025.
Mannkind (MNKD) Cash & Current Investments (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Cash & Current Investments data on file, last reported at $134.6 million in Q1 2026.
- Cash & Current Investments for Q1 2026 came in at $134.6 million, down 26.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $134.6 million (down 26.15% YoY), and the FY2025 annual result was $171.3 million, down 13.46% from the prior year.
- Cash & Current Investments retreated to $134.6 million in Q1 2026 per MNKD's latest filing, from $171.3 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $300.7 million in Q1 2024 and troughed at $134.6 million in Q1 2026.
- A 5-year average of $195.6 million and a median of $171.3 million in 2025 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2022 and 2024: Cash & Current Investments tumbled 41.34% in 2022, then soared 81.01% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $170.8 million in 2022, then jumped by 72.73% to $295.1 million in 2023, then tumbled by 32.91% to $198.0 million in 2024, then dropped by 13.46% to $171.3 million in 2025, then slipped by 21.44% to $134.6 million in 2026.
- Business Quant data shows MNKD's Cash & Current Investments at $134.6 million in Q1 2026, $171.3 million in Q4 2025, and $260.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn | 134.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134.61 Mn |
| Dec 31, 2025 | 171.35 Mn |
| Sep 30, 2025 | 260.04 Mn |
| Jun 30, 2025 | 178.99 Mn |
| Mar 31, 2025 | 182.28 Mn |
| Dec 31, 2024 | 197.99 Mn |
| Sep 30, 2024 | 252.32 Mn |
| Jun 30, 2024 | 248.49 Mn |
| Mar 31, 2024 | 300.73 Mn |
| Dec 31, 2023 | 295.10 Mn |
| Sep 30, 2023 | 141.02 Mn |
| Jun 30, 2023 | 144.35 Mn |
| Mar 31, 2023 | 166.14 Mn |
| Dec 31, 2022 | 170.85 Mn |
| Sep 30, 2022 | 165.05 Mn |
| Jun 30, 2022 | 154.15 Mn |
| Mar 31, 2022 | 162.40 Mn |
| Dec 31, 2021 | 204.12 Mn |
| Sep 30, 2021 | 139.01 Mn |
| Jun 30, 2021 | 162.47 Mn |